Spots Global Cancer Trial Database for Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Official Title: Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome

Study ID: NCT00104962

Conditions

Childhood Myelodysplastic Syndromes

de Novo Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes

Refractory Anemia

Refractory Anemia With Excess Blasts

Refractory Anemia With Ringed Sideroblasts

Refractory Cytopenia With Multilineage Dysplasia

Secondary Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

lenalidomide

Study Description

Brief Summary: This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes. Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.

Detailed Description: PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose and recommended phase II dose of lenalidomide in pediatric patients with relapsed or refractory solid tumors. II. Determine the toxic effects of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients. SECONDARY OBJECTIVES: I. Determine, preliminarily, the feasibility of administering this drug to pediatric patients with relapsed or refractory myelodysplastic syndromes. II. Determine, preliminarily, the antitumor activity of this drug in both patient populations. III. Determine immunologic changes in patients treated with this drug. OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to diagnosis (solid tumor vs myelodysplastic syndromes \[MDS\]). Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients with solid tumors receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients with MDS receive a fixed dose (do not undergo dose escalation) of lenalidomide. After completion of study treatment, patients are followed annually. PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.